Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
LY2510924
i
Other names:
LY2510924, LY 2510924, T-134, anti-CXCR4 peptide, LY-2510924, T 134
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Eli Lilly
Drug class:
CXCR4 antagonist
Related drugs:
‹
GMI-1359 (4)
mavorixafor (3)
POL 6326 (3)
BMS-936564 (1)
AT 009 (0)
motixafortide (0)
PTX-9908 (0)
GPC-100 (0)
CX-01 (0)
plerixafor (0)
GMI-1359 (4)
mavorixafor (3)
POL 6326 (3)
BMS-936564 (1)
AT 009 (0)
motixafortide (0)
PTX-9908 (0)
GPC-100 (0)
CX-01 (0)
plerixafor (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
quizartinib + LY2510924
Sensitive: D – Preclinical
quizartinib + LY2510924
Sensitive
:
D
quizartinib + LY2510924
Sensitive: D – Preclinical
quizartinib + LY2510924
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login